Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Ondra Health vs Claya

Two GLP-1 deals, scored on the same six factors. Ondra Health lands a Value Score of 92, Claya a 75. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Ondra Health

#2 · Grade A+ · Best Value

Est. first month

$93/mo

Save ~93% vs brand-name
Get this deal Full Ondra Health review →
VS

Claya

#127 · Grade C+ · Fair Price

Est. first month

From $179/mo (starting dose, compounded)

Save ~87% vs brand-name
Get this deal Full Claya review →

The verdict

Better value: Ondra Health

Ondra Health takes it on Value Score, 92 to 75 an est. $93/mo first month, with no teaser step-up baked in. Claya isn't out of it: Shoppers who want compounded GLP-1 in injectable and oral-tablet forms with named clinicians.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealOndra HealthClaya
Value Score92 (A+)75 (C+)
Est. first month$93/moFrom $179/mo (starting dose, compounded)
Save vs brand-name~93%~87%
Semaglutide$93/moFrom $179/mo (starting dose, compounded)
Tirzepatide$166/moFrom $279/mo (starting dose, compounded)
Both moleculesYesYes
PricingFlat — no step-upWatch
CoverageAll 50 statesCoverage not published

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

96
Lowest Real Price
76
Ondra Health: 96. Claya: 76.
88
No Teaser-Rate Bait
64
Ondra Health: 88. Claya: 64.
98
Nationwide Availability
45
Ondra Health: 98. Claya: 45.
92
Both Molecules
98
Ondra Health: 92. Claya: 98.
84
Easy Cancellation
95
Ondra Health: 84. Claya: 95.
84
Reputation
73
Ondra Health: 84. Claya: 73.

Ondra Health

The cheapest flat semaglutide sticker we track ($93) — LegitScript-certified, all 50 states, and it still offers brand-name access.

Why it's a deal

  • Lowest disclosed flat semaglutide price in the roster ($93/mo) — no teaser step-up
  • LegitScript-certified and available in all 50 states
  • Offers FDA-approved brand-name access alongside compounded
  • Tirzepatide is competitive too at $166/mo

The fine print

  • Newer name with a shorter public track record than the established flat-fee brands
  • No oral/sublingual route for the needle-averse

Claya

Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

Why it's a deal

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

The fine print

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Get the Ondra Health deal Get the Claya deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Ondra Health is ranked on the Ondra Health alternatives board, and the same list for the other side is on alternatives to Claya.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.